Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Swedes Explain Why They Should Have the EMA ‘Gem’ After Brexit

Executive Summary

Sweden explains the reasons why the European Medicines Agency should move there from London once the UK leaves the EU, citing an established life sciences network, a strong R&D sector, and a solid biopharmaceutical industry base.

You may also be interested in...



Race Hots Up For EMA After Brexit

France has officially named Lille as the city it would like to host the European Medicines Agency once the UK leaves the EU, and Italy has appointed an ambassador to promote Milan’s bid for the agency. Meanwhile, stakeholders in Denmark are joining forces to stress why Copenhagen would be a good choice, and Ireland, the Netherlands and Austria have all confirmed their candidacies.

‘Virtually Bribery And Corruption Free’ Denmark With Its Clean Canals Says ‘Give Us EMA’

The UK is on track to start formal EU exit negotiations in March, Denmark has announced its official candidacy to host the European Medicines Agency post-Brexit, and details are emerging on the campaigns that other contenders for the EMA, such as Ireland and Italy, are waging.

EMA Post-Brexit: 'It Can’t Stay In The UK' … Or Can It?

The assumption to date has been that the European Medicines Agency will have to move from its London base when the UK leaves the EU. But things may not be quite that simple.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS119164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel